Skip to main content
. Author manuscript; available in PMC: 2011 Aug 9.
Published in final edited form as: J Neurooncol. 2010 Nov 30;104(1):83–92. doi: 10.1007/s11060-010-0473-5

Figure 4. Combination therapy with anti-CCL2 mAb(s) and TMZ.

Figure 4

C57BL/6 mice bearing GL261 glioma (a) or SCID mice bearing human U87 glioma (b) were stratified into one of four treatment groups (in each model) to receive: 1) TMZ and anti-CCL2 mAb(s) (n=10); 2) TMZ and control isotype IgG, (n=7); 3) saline (control for TMZ) and anti-CCL2 mAb(s), (n=10) or 4) saline and isotype IgG (n=7). For mAb treatment, the mice received anti-mouse CCL2 mAb or both anti-mouse CCL2 mAb and anti-human CCL2 mAb, respectively, by i.p. injections starting on day 7, twice weekly up to 8 weeks after tumor cell inoculation (2 mg/kg/dose for each mAb). TMZ (800 ug/dose) was administered i.p. starting on day 7 after tumor inoculation for a total of 2 or 3 cycles in C57BL/6 or SCID mice, respectively (see Materials and Methods). SFS of mice was monitored. (a), *p=0.0002 for anti-CCL2 mAb and saline vs. isotype IgG and saline; **p=0.0002 for isotype IgG and TMZ vs. isotype IgG and saline; ***p<0.0001 for anti-CCL2 mAb and TMZ vs. isotype IgG and saline; #p=0.0359 for anti-CCL2 mAb and TMZ vs. isotype IgG and TMZ. (b), *p=0.0218 for anti-CCL2 mAbs and saline vs. isotype IgG and saline; **p<0.0001 for isotype IgG and TMZ vs. isotype IgG and saline; ***p<0.0001 for anti-CCL2 mAbs and TMZ vs. isotype IgGs and saline; p=0.7645 for anti-CCL2 mAbs and TMZ vs. isotype IgGs and TMZ. α-mCCL2 refers to anti-mouse CCL2 antibody; α-hCCL2 refers to anti-human CCL2 antibody.